Editas Medicine - EDIT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.92
  • Forecasted Upside: 29.58%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.09 (0.85%)

This chart shows the closing price for EDIT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Editas Medicine Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EDIT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EDIT

Analyst Price Target is $13.92
▲ +29.58% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $13.92, with a high forecast of $30.00 and a low forecast of $7.00. The average price target represents a 29.58% upside from the last price of $10.74.

This chart shows the closing price for EDIT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 12 investment analysts is to hold stock in Editas Medicine. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/24/2023CitigroupUpgradeNeutral ➝ Buy$11.00Low
10/18/2023JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$8.00Low
10/17/2023Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
9/28/2023Stifel NicolausUpgradeHold ➝ Buy$9.00 ➝ $17.00Low
9/13/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$14.00Low
8/29/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$14.00Low
8/3/2023OppenheimerReiterated RatingMarket Perform ➝ Market Perform$12.00Low
8/2/2023Chardan CapitalLower TargetBuy ➝ Buy$22.00 ➝ $19.00Low
6/12/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$17.00Low
2/23/2023Credit Suisse GroupBoost TargetNeutral$13.00 ➝ $15.00Low
2/23/2023Royal Bank of CanadaLower TargetSector Perform$14.00 ➝ $10.00Low
2/23/2023Chardan CapitalLower TargetBuy$35.00 ➝ $22.00Low
2/23/2023Wells Fargo & CompanyLower Target$36.00 ➝ $30.00Low
1/31/2023Cantor FitzgeraldInitiated CoverageOverweight$15.00Low
1/24/2023Morgan StanleyLower TargetUnderweight$8.00 ➝ $7.00Low
1/23/2023SVB LeerinkBoost TargetMarket Perform$6.00 ➝ $7.00Low
1/10/2023SVB LeerinkLower TargetMarket Perform$7.00 ➝ $6.00Low
1/4/2023Wells Fargo & CompanyLower TargetOverweight$50.00 ➝ $36.00Low
12/13/2022CitigroupInitiated CoverageNeutral$11.00Low
12/6/2022Credit Suisse GroupReiterated RatingNeutral$13.00Low
11/21/2022Evercore ISILower Target$8.00Low
11/18/2022Bank of AmericaLower TargetNeutral$18.00 ➝ $15.00Low
11/18/2022Morgan StanleyLower TargetUnderweight$10.00 ➝ $8.00Low
11/18/2022Royal Bank of CanadaLower TargetSector Perform$32.00 ➝ $14.00Low
11/18/2022Truist FinancialLower TargetBuy$80.00 ➝ $35.00Low
11/18/2022Robert W. BairdLower TargetOutperform$25.00 ➝ $18.00Low
11/17/2022Credit Suisse GroupDowngradeOutperform ➝ Neutral$25.00 ➝ $13.00Low
11/17/2022Chardan CapitalLower TargetBuy$43.00 ➝ $35.00Low
11/17/2022OppenheimerDowngradeOutperform ➝ Market Perform$28.00 ➝ $12.00Low
11/17/2022SVB LeerinkLower TargetMarket Perform$14.00 ➝ $7.00Low
11/8/2022Morgan StanleyLower TargetUnderweight$15.00 ➝ $10.00Low
11/3/2022Royal Bank of CanadaLower TargetSector Perform$40.00 ➝ $32.00Low
11/3/2022Robert W. BairdLower TargetOutperform$30.00 ➝ $25.00Low
11/3/2022SVB LeerinkLower TargetMarket Perform$14.00 ➝ $12.00Low
11/2/2022Chardan CapitalLower TargetBuy$60.00 ➝ $43.00Low
9/29/2022Bank of AmericaInitiated CoverageNeutral$18.00Low
8/4/2022BarclaysBoost TargetEqual Weight$16.00 ➝ $17.00Low
5/24/2022The Goldman Sachs GroupLower TargetSell$10.00 ➝ $8.00Medium
5/5/2022OppenheimerLower Target$55.00 ➝ $28.00High
4/18/2022Robert W. BairdLower Target$44.00 ➝ $33.00High
4/12/2022Morgan StanleyBoost TargetUnderweight$16.00 ➝ $17.00Medium
2/25/2022BarclaysLower Target$39.00 ➝ $18.00High
2/25/2022Chardan CapitalLower TargetBuy$75.00 ➝ $60.00High
2/25/2022OppenheimerLower TargetOutperform$80.00 ➝ $55.00High
2/25/2022SVB LeerinkLower TargetMarket Perform$41.00 ➝ $27.00High
2/11/2022Evercore ISIDowngradeHold$15.00High
1/6/2022Morgan StanleyLower TargetUnderweight$37.00 ➝ $24.00Low
10/20/2021Robert W. BairdReiterated RatingBuyMedium
10/19/2021SVB LeerinkInitiated CoverageMarket Perform$41.00Medium
9/30/2021Chardan CapitalReiterated RatingBuy$75.00Medium
9/30/2021Stifel NicolausLower TargetHold$65.00 ➝ $46.00High
9/23/2021Stifel NicolausInitiated CoverageHold$65.00High
9/9/2021OppenheimerUpgradeMarket Perform ➝ Outperform$42.00 ➝ $80.00Medium
8/9/2021Truist FinancialUpgradeBuy$80.00Low
8/5/2021Evercore ISIUpgradeUnderperform ➝ Outperform$20.00 ➝ $60.00High
7/7/2021Chardan CapitalReiterated RatingBuyMedium
5/10/2021Morgan StanleyLower TargetUnderweight$40.00 ➝ $37.00High
5/3/2021Royal Bank of CanadaInitiated CoverageSector Perform$40.00High
4/16/2021The Goldman Sachs GroupInitiated CoverageSell$20.00High
3/22/2021Credit Suisse GroupInitiated CoverageOutperform$58.00High
3/8/2021BarclaysReiterated RatingOverweight ➝ Equal Weight$46.00Medium
3/2/2021Morgan StanleyLower TargetUnderweight$45.00 ➝ $40.00Medium
3/1/2021BarclaysDowngradeOverweight ➝ Equal Weight$46.00Low
2/28/2021JPMorgan Chase & Co.Reiterated RatingSell$30.00Low
2/26/2021Truist FinancialDowngradeBuy ➝ Hold$45.00Low
2/25/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$30.00Medium
2/10/2021Chardan CapitalBoost TargetBuy$55.00 ➝ $77.00Low
1/20/2021JPMorgan Chase & Co.Reiterated RatingHoldLow
1/19/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$64.00 ➝ $45.00Low
1/13/2021Wells Fargo & CompanyBoost TargetOverweight$69.00 ➝ $86.00Medium
1/7/2021Raymond JamesDowngradeOutperform ➝ Market PerformN/A
12/16/2020Morgan StanleyBoost TargetEqual Weight$30.00 ➝ $64.00Low
12/10/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$28.00 ➝ $69.00High
11/11/2020Morgan StanleyLower TargetEqual Weight$31.00 ➝ $30.00High
11/6/2020Raymond JamesLower TargetOutperform$65.00 ➝ $60.00Medium
11/2/2020Robert W. BairdInitiated CoverageUnderperform$14.00High
10/13/2020Morgan StanleyLower TargetEqual Weight$32.00 ➝ $31.00Medium
8/10/2020Morgan StanleyBoost TargetEqual Weight$27.00 ➝ $32.00Low
8/7/2020Raymond JamesBoost TargetOutperform$46.00 ➝ $65.00High
6/18/2020SunTrust BanksInitiated CoverageBuy$45.00High
6/15/2020OppenheimerReiterated RatingHoldHigh
6/12/2020Chardan CapitalReiterated RatingBuy$55.00High
5/11/2020Morgan StanleyLower TargetEqual Weight$30.00 ➝ $27.00High
5/7/2020OppenheimerInitiated CoverageHoldMedium
3/4/2020Chardan CapitalReiterated RatingBuy$55.00High
2/27/2020Raymond JamesLower TargetOutperform$44.00 ➝ $41.00High
2/27/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
2/21/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$28.00High
12/10/2019Chardan CapitalReiterated RatingBuy$55.00Low
8/9/2019Morgan StanleySet TargetHold$29.00High
7/25/2019Chardan CapitalReiterated RatingBuy$55.00Medium
6/16/2019Chardan CapitalSet TargetBuy$55.00Medium
5/8/2019OppenheimerReiterated RatingHoldMedium
4/11/2019Evercore ISIInitiated CoverageOutperformMedium
2/7/2019BTIG ResearchInitiated CoverageBuy$30.00Low
1/22/2019JPMorgan Chase & Co.Reiterated RatingHoldHigh
1/22/2019CowenReiterated RatingBuyMedium
1/22/2019Chardan CapitalReiterated RatingBuy$55.00High
1/10/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
12/31/2018SunTrust BanksReiterated RatingBuyHigh
(Data available from 11/28/2018 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 10 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 5 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Editas Medicine logo
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $10.74
Low: $10.38
High: $10.80

50 Day Range

MA: $7.76
Low: $6.25
High: $10.84

52 Week Range

Now: $10.74
Low: $6.08
High: $11.93


1,495,096 shs

Average Volume

1,809,151 shs

Market Capitalization

$877.14 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Editas Medicine?

The following Wall Street analysts have issued reports on Editas Medicine in the last year: Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Credit Suisse Group AG, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, and Wells Fargo & Company.
View the latest analyst ratings for EDIT.

What is the current price target for Editas Medicine?

12 Wall Street analysts have set twelve-month price targets for Editas Medicine in the last year. Their average twelve-month price target is $13.92, suggesting a possible upside of 29.6%. Wells Fargo & Company has the highest price target set, predicting EDIT will reach $30.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $7.00 for Editas Medicine in the next year.
View the latest price targets for EDIT.

What is the current consensus analyst rating for Editas Medicine?

Editas Medicine currently has 1 sell rating, 6 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EDIT, but not buy more shares or sell existing shares.
View the latest ratings for EDIT.

What other companies compete with Editas Medicine?

How do I contact Editas Medicine's investor relations team?

Editas Medicine's physical mailing address is 11 Hurley Street, Cambridge MA, 02141. The company's listed phone number is (617) 401-9000 and its investor relations email address is mark.mull[email protected]. The official website for Editas Medicine is www.editasmedicine.com. Learn More about contacing Editas Medicine investor relations.